Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: Turner syndrome
CADTH
Record ID 32014000803
English
Authors' recommendations:
Based on the findings of two systematic reviews, it appears that somatropin treatment results in greater and more rapid gains in height, including final height, compared with no treatment. However, whether QoL is improved in those treated with somatropin compared with those not treated is uncertain. Genotropin is one of several somatropin products approved by Health Canada for the treatment of short stature associated with TS; others include Humatrope, Nutropin, and Saizen. There is insufficient evidence on the comparative efficacy and safety of the somatropin products for the treatment of short stature associated with TS. In clinical practice, product selection is generally based upon patient and/or parent preference in consultation with the clinician.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/clinical/SR0334_GenotropinTS_CL_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Turner Syndrome
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.